Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas O Connor

Vascular Surgery Lancaster, PA Doctor of Osteopathy

NPI 1144213992 CMS profile 509656

2102 Harrisburg Pike, Lancaster, PA 17601

Open in the dashboard

General payments

$14,496

23 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas O Connor of Lancaster, PA is reported in the CMS Open Payments database as having received $14,496 across 23 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122 2
2022 General $122 2
2021 General $26 2
2020 General $6,069 4
2019 General $8,156 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas O Connor
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Thomas O Connor were reported at $122. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Thomas O Connor Vascular Surgery median Middle half National median
2019 $8,156 $796 $226–$2,363 $163
2020 $6,069 $348 $118–$1,110 $114
2021 $26 $471 $158–$1,421 $132
2022 $122 $725 $222–$2,183 $149
2023 $0 $836 $257–$2,440 $160
2024 $0 $909 $252–$2,619 $164
2025 $122 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $14,156 15 payments
  2. Medtronic, Inc. $124 2 payments
  3. W. L. Gore & Associates, Inc. $90 1 payment
  4. Silk Road Medical, Inc. $69 2 payments
  5. Stryker Corporation $32 1 payment
  6. Eyevance Pharmaceuticals LLC $13 1 payment
  7. Cook Medical LLC $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $13,000 4 payments
  2. Travel and Lodging $863 3 payments
  3. Food and Beverage $634 16 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $14,156 15 payments
  2. ENDURANT IIS $109 1 payment
  3. EXCLUDER Conformable AAA Endoprosthesis with Active Control $90 1 payment
  4. ENROUTE Transcarotid Neuroprotection System $69 2 payments
  5. ENROUTE Transcarotid Stent System $69 2 payments
  6. ENHANCE Transcarotid Peripheral Access Kit $69 2 payments
  7. ENROUTE 0.014 Guidewire $69 2 payments
  8. FLOWTRIEVER $32 1 payment
  9. MVP $15 1 payment
  10. Flarex $13 1 payment
  11. Other $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

320

Median for Vascular Surgery: 122

Drug cost

$1,492

Median for Vascular Surgery: $14,135

Branded share of claims

55.6%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cilostazol Generic 61 $656
Clopidogrel Clopidogrel Bisulfate Brand 178 $567
Atorvastatin Calcium Generic 30 $178
Oxycodone Hcl Generic 51 $91

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 103 billing codes

Paid by Medicare

$129,376

Medicare's payments for the services billed

Medicare patients

551

Average age 75

Services billed

1,164

222 women, 329 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 53%
Ischemic heart disease 52%
Arthritis 51%
Diabetes 48%
Heart failure 37%
Depression 30%
Atrial fibrillation 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record